Seppo W Langer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/9723241/publications.pdf

Version: 2024-02-01

100 papers	3,474 citations	172457 29 h-index	155660 55 g-index
102 all docs	102 docs citations	102 times ranked	3745 citing authors

#	Article	IF	Citations
1	Prospective Phase II Trial of Prognostication by ⁶⁸Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy. Journal of Nuclear Medicine, 2022, 63, 1371-1377.	5.0	13
2	Clinical features affecting efficacy of immune checkpoint inhibitors in pretreated patients with advanced NSCLC: a Danish nationwide real-world study. Acta OncolÃ³gica, 2022, 61, 409-416.	1.8	11
3	Patient-reported health-related quality of life from a randomized phase II trial comparing standard-dose with high-dose twice daily thoracic radiotherapy in limited stage small-cell lung cancer. Lung Cancer, 2022, 166, 49-57.	2.0	1
4	Activity Dose Reduction in 64Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Impact on Image Quality and Lesion Detection Ability. Molecular Imaging and Biology, 2022, 24, 600-611.	2.6	1
5	Surgery in Patients with Gastro-Entero-Pancreatic Neuroendocrine Carcinomas, Neuroendocrine Tumors G3 and High Grade Mixed Neuroendocrine-Non-Neuroendocrine Neoplasms. Current Treatment Options in Oncology, 2022, 23, 806-817.	3.0	13
6	Long-term outcomes after video-assisted thoracoscopic surgery in pulmonary large-cell neuroendocrine carcinoma. Surgical Oncology, 2022, 41, 101728.	1.6	5
7	A Consensus-Developed Morphological Re-Evaluation of 196 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms and Its Clinical Correlations. Neuroendocrinology, 2021, 111, 883-894.	2.5	54
8	¹⁸F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study. Journal of Nuclear Medicine, 2021, 62, 808-815.	5.0	53
9	¹⁸F-FLT PET/CT Adds Value to ¹⁸F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical Trial. Journal of Nuclear Medicine, 2021, 62, 628-635.	5.0	8
10	Prognostic Value of 18Fâ€“FDGâ€“PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature. Diagnostics, 2021, 11, 174.	2.6	9
11	Impact of [18F]FDG-PET and [18F]FLT-PET-Parameters in Patients with Suspected Relapse of Irradiated Lung Cancer. Diagnostics, 2021, 11, 279.	2.6	3
12	Semiautomatic Tumor Delineation for Evaluation of ⁶⁴Cu-DOTATATE PET/CT in Patients with Neuroendocrine Neoplasms: Prognostication Based on Lowest Lesion Uptake and Total Tumor Volume. Journal of Nuclear Medicine, 2021, 62, 1564-1570.	5.0	20
13	Initial Experience with 64Cu-DOTATATE Digital PET of Patients with Neuroendocrine Neoplasms: Comparison with Analog PET. Diagnostics, 2021, 11, 350.	2.6	3
14	Surgery of the primary tumour in 201 patients with highâ€grade gastroenteropancreatic neuroendocrine and mixed neuroendocrineâ€non‐neuroendocrine neoplasms. Journal of Neuroendocrinology, 2021, 33, e12967.	2.6	23
15	High-dose versus standard-dose twice-daily thoracic radiotherapy for patients with limited stage small-cell lung cancer: an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2021, 22, 321-331.	10.7	74
16	A short report of 50 patients with gastroenteropancreatic mixed neuroendocrineâ€“non-neuroendocrine neoplasms (MiNEN). Acta OncolÃ³gica, 2021, 60, 808-812.	1.8	7
17	Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta OncolÃ³gica, 2021, 60, 931-941.	1.8	32
18	Neuroendocrine neoplasms of the appendix: Characterization of 335 patients referred to the Copenhagen NET Center of Excellence. European Journal of Surgical Oncology, 2021, 47, 1357-1363.	1.0	16

#	Article	IF	Citations
19	Long-term survival and recurrence after resection of bronchopulmonary carcinoids: A single-center cohort study of 236 patients. Lung Cancer, 2021, 156, 109-116.	2.0	13
20	Increase of Kiâ€67 index and influence on mortality in patients with neuroendocrine neoplasms. Journal of Neuroendocrinology, 2021, 33, e13018.	2.6	6
21	Nationwide Survival Benefit after Implementation of First-Line Immunotherapy for Patients with Advanced NSCLCâ€"Real World Efficacy. Cancers, 2021, 13, 4846.	3.7	19
22	⁶⁴Cu-DOTATATE PET in Patients with Neuroendocrine Neoplasms: Prospective, Head-to-Head Comparison of Imaging at 1 Hour and 3 Hours After Injection. Journal of Nuclear Medicine, 2021, 62, 73-80.	5.0	29
23	Incidence, Clinical Presentation and Trends in Indication for Diagnostic Work-Up of Small Intestinal and Pancreatic Neuroendocrine Tumors. Diagnostics, 2021, 11, 2030.	2.6	12
24	Limited Diagnostic Utility of Chromogranin A Measurements in Workup of Neuroendocrine Tumors. Diagnostics, 2020, 10, 881.	2.6	7
25	Effects of an exercise intervention for patients with advanced inoperable lung cancer undergoing chemotherapy: A randomized clinical trial. Lung Cancer, 2020, 145, 76-82.	2.0	43
26	⁶⁴Cu-DOTATATE PET/CT and Prediction of Overall and Progression-Free Survival in Patients with Neuroendocrine Neoplasms. Journal of Nuclear Medicine, 2020, 61, 1491-1497.	5.0	27
27	Management Recommendations for Merkel Cell Carcinomaâ€"A Danish Perspective. Cancers, 2020, 12, 554.	3.7	15
28	Early initiated postoperative rehabilitation enhances quality of life in patients with operable lung cancer: Secondary outcomes from a randomized trial. Lung Cancer, 2020, 146, 285-289.	2.0	13
29	P53, Somatostatin receptor 2a and Chromogranin A immunostaining as prognostic markers in high grade gastroenteropancreatic neuroendocrine neoplasms. BMC Cancer, 2020, 20, 27.	2.6	34
30	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients â€“ initial observations. PLoS ONE, 2020, 15, e0231884.	2.5	11
31	PD-L1 expression in gastroenteropancreatic neuroendocrine neoplasms grade 3. PLoS ONE, 2020, 15, e0243900.	2.5	11
32	18F-fluorothymidine (FLT)-PET and diffusion-weighted MRI for early response evaluation in patients with small cell lung cancer: a pilot study. European Journal of Hybrid Imaging, 2020, 4, 2.	1.5	2
33	Title is missing!. , 2020, 15, e0231884.		0
34	Title is missing!. , 2020, 15, e0231884.		0
35	Title is missing!. , 2020, 15, e0231884.		0
36	Title is missing!. , 2020, 15, e0231884.		0

#	Article	IF	Citations
37	Improving the prognosis for lung cancer patients. Acta OncolÃ³gica, 2019, 58, 1077-1078.	1.8	11
38	Surgical Management, Preoperative Tumor Localization, and Histopathology of 80 Patients Operated on for Insulinoma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 6129-6138.	3.6	28
39	Very Early Response Evaluation by PET/MR in Patients with Lung Cancerâ€"Timing and Feasibility. Diagnostics, 2019, 9, 35.	2.6	5
40	Intravenous versus oral etoposide: efficacy and correlation to clinical outcome in patients with high-grade metastatic gastroenteropancreatic neuroendocrine neoplasms (WHO G3). Medical Oncology, 2018, 35, 47.	2.5	13
41	A Competing Risk Model of First Failure Site after Definitive Chemoradiation Therapy for Locally Advanced Nonâ€"Small Cell Lung Cancer. Journal of Thoracic Oncology, 2018, 13, 559-567.	1.1	16
42	Changes in Health-Related Quality of Life During Rehabilitation in Patients With Operable Lung Cancer: A Feasibility Study (PROLUCA). Integrative Cancer Therapies, 2018, 17, 388-400.	2.0	18
43	Reproducibility of MR-Based Attenuation Maps in PET/MRI and the Impact on PET Quantification in Lung Cancer. Journal of Nuclear Medicine, 2018, 59, 999-1004.	5.0	15
44	Pancreatic Islet Cell Tumors. , 2018, , 626-634.		0
45	Early initiated postoperative rehabilitation reduces fatigue in patients with operable lung cancer: A randomized trial. Lung Cancer, 2018, 126, 125-132.	2.0	39
46	Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients. American Journal of Nuclear Medicine and Molecular Imaging, 2018, 8, 127-136.	1.0	2
47	Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. European Journal of Surgical Oncology, 2017, 43, 1682-1689.	1.0	46
48	Head-to-Head Comparison of ⁶⁴Cu-DOTATATE and ⁶⁸Ga-DOTATOC PET/CT: A Prospective Study of 59 Patients with Neuroendocrine Tumors. Journal of Nuclear Medicine, 2017, 58, 451-457.	5.0	163
49	Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. Diagnostics, 2017, 7, 23.	2.6	13
50	Expression of p53 protein in high-grade gastroenteropancreatic neuroendocrine carcinoma. PLoS ONE, 2017, 12, e0187667.	2.5	24
51	Primary pulmonary adenocarcinoma in a 16-year-old boy â€" a five-year follow-up. European Clinical Respiratory Journal, 2016, 3, 32633.	1.5	3
52	Perioperative Rehabilitation in Operable Lung Cancer Patients (PROLUCA). Integrative Cancer Therapies, 2016, 15, 455-466.	2.0	34
53	Prognostic Value of 18F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18F-FDG PET and Ki-67 in 100 Patients. Journal of Nuclear Medicine, 2016, 57, 1851-1857.	5.0	29
54	Early lesion-specific 18F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. Radiotherapy and Oncology, 2016, 118, 460-464.	0.6	11

#	Article	IF	Citations
55	Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. Annals of Surgical Oncology, 2016, 23, 1721-1728.	1.5	73
56	Diagnosis and treatment of bronchopulmonary neuroendocrine tumours: State of the art. Acta OncolÃ³gica, 2016, 55, 3-14.	1.8	15
57	(68)Ga-DOTATOC PET and gene expression profile in patients with neuroendocrine carcinomas: strong correlation between PET tracer uptake and gene expression of somatostatin receptor subtype 2. American Journal of Nuclear Medicine and Molecular Imaging, 2016, 6, 59-72.	1.0	14
58	Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics, 2015, 5, 119-176.	2.6	87
59	Goblet Cell Carcinoids: Characteristics of a Danish Cohort of 83 Patients. PLoS ONE, 2015, 10, e0117627.	2.5	26
60	Cowden Syndrome and Concomitant Pulmonary Neuroendocrine Tumor: A Presentation of Two Cases. Case Reports in Medicine, 2015, 2015, 1-4.	0.7	4
61	⁶⁴Cu-DOTATATE for Noninvasive Assessment of Atherosclerosis in Large Arteries and Its Correlation with Risk Factors: Head-to-Head Comparison with ⁶⁸Ga-DOTATOC in 60 Patients. Journal of Nuclear Medicine, 2015, 56, 1895-1900.	5.0	67
62	⁶⁴Cu-DOTATATE PET for Neuroendocrine Tumors: A Prospective Head-to-Head Comparison with ¹¹¹In-DTPA-Octreotide in 112 Patients. Journal of Nuclear Medicine, 2015, 56, 847-854.	5.0	115
63	The Impact of a Multidimensional Exercise Intervention on Physical and Functional Capacity, Anxiety, and Depression in Patients With Advanced-Stage Lung Cancer Undergoing Chemotherapy. Integrative Cancer Therapies, 2015, 14, 341-349.	2.0	82
64	Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Management and Research, 2014, 6, 357.	1.9	72
65	Topotecan Monotherapy in Heavily Pretreated Patients with Progressive Advanced Stage Neuroendocrine Carcinomas. Journal of Cancer, 2014, 5, 628-632.	2.5	39
66	PET/CT in therapy evaluation of patients with lung cancer. Expert Review of Anticancer Therapy, 2014, 14, 595-620.	2.4	8
67	Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms. Acta OncolÃ³gica, 2014, 53, 1284-1297.	1.8	99
68	Perioperative rehabilitation in operation for lung cancer (PROLUCA) â€“ rationale and design. BMC Cancer, 2014, 14, 404.	2.6	22
69	â€œEXHALEâ€ exercise as a strategy for rehabilitation in advanced stage lung cancer patients: a randomized clinical trial comparing the effects of 12Âweeks supervised exercise intervention versus usual care for advanced stage lung cancer patients. BMC Cancer, 2013, 13, 477.	2.6	26
70	Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Annals of Oncology, 2013, 24, 152-160.	1.2	792
71	First-line treatment of patients with disseminated poorly differentiated neuroendocrine carcinomas with carboplatin, etoposide, and vincristine: A single institution experience. Acta OncolÃ³gica, 2012, 51, 97-100.	1.8	15
72	A placebo-controlled, randomized phase II study of maintenance enzastaurin following whole brain radiation therapy in the treatment of brain metastases from lung cancer. Lung Cancer, 2012, 78, 63-69.	2.0	22

#	Article	IF	Citations
73	Temozolomide as Second or Third Line Treatment of Patients with Neuroendocrine Carcinomas. Scientific World Journal, The, 2012, 2012, 1-4.	2.1	57
74	Treatment of experimental extravasation of amrubicin, liposomal doxorubicin, and mitoxantrone with dexrazoxane. Cancer Chemotherapy and Pharmacology, 2012, 69, 573-576.	2.3	12
75	RE: Kesik et al: Melatonin Ameliorates Doxorubicin-induced Skin Necrosis in Rats. Annals of Plastic Surgery, 2010, 65, 511.	0.9	1
76	A murine experimental anthracycline extravasation model: Pathology and study of the involvement of topoisomerase II alpha and iron in the mechanism of tissue damage. Toxicology, 2010, 269, 67-72.	4.2	15
77	Extravasation of Chemotherapy. Current Oncology Reports, 2010, 12, 242-246.	4.0	32
78	A Recall Reaction and Call for Action. Onkologie, 2010, 33, 85-86.	0.8	1
79	Anthracycline Extravasation: A Comprehensive Review of Experimental and Clinical Treatments. Tumori, 2009, 95, 273-282.	1.1	27
80	Anthracycline extravasation: a comprehensive review of experimental and clinical treatments. Tumori, 2009, 95, 273-82.	1.1	5
81	Treatment of anthracycline extravasation from centrally inserted venous catheters. Oncology Reviews, 2008, 2, 114-116.	1.8	16
82	Topotecan and cisplatin in combination with concurrent twice-daily chemoradiation in limited disease small cell lung cancerâ€"a Danish Oncological Lung Cancer Group (DOLG) phase II trial. Lung Cancer, 2008, 60, 252-258.	2.0	10
83	Phase II Study of a 3-Day Schedule with Topotecan and Cisplatin in Patients with Previously Untreated Small Cell Lung Cancer and Extensive Disease. Journal of Thoracic Oncology, 2008, 3, 902-906.	1.1	7
84	A prospective study of PET/CT in initial staging of small-cell lung cancer: comparison with CT, bone scintigraphy and bone marrow analysis. Annals of Oncology, 2007, 18, 338-345.	1.2	149
85	Dexrazoxane for anthracycline extravasation. Expert Review of Anticancer Therapy, 2007, 7, 1081-1088.	2.4	12
86	Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Annals of Oncology, 2007, 18, 546-550.	1.2	136
87	Metastasizing malignant pleomorphic adenoma in a young man. Apmis, 2007, 115, 866-868.	2.0	2
88	Randomized, double-blind trial comparing the antiemetic effect of tropisetron plus metopimazine with tropisetron plus placebo in patients receiving multiple cycles of multiple-day cisplatin-based chemotherapy. Supportive Care in Cancer, 2007, 15, 417-426.	2.2	18
89	Other uses of dexrazoxane: savene, the first proven antidote against anthracycline extravasation injuries. Cardiovascular Toxicology, 2007, 7, 151-153.	2.7	11
90	PET/CT imaging in response evaluation of patients with small cell lung cancer. Lung Cancer, 2006, 54, 41-49.	2.0	54

#	Article	IF	Citations
91	Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemotherapy and Pharmacology, 2006, 57, 125-128.	2.3	53
92	Pharmacokinetics of etoposide in cancer patients treated with high-dose etoposide and with dexrazoxane (ICRF-187) as a rescue agent. Cancer Chemotherapy and Pharmacology, 2004, 53, 91-93.	2.3	6
93	Metabolism of dexrazoxane (ICRF-187) used as a rescue agent in cancer patients treated with high-dose etoposide. Cancer Chemotherapy and Pharmacology, 2003, 52, 167-174.	2.3	31
94	DEXRAZOXANE - A PROMISING ANTIDOTE IN THE TREATMENT OF ACCIDENTAL EXTRAVASATION OF ANTHRACYCLINES. Scandinavian Journal of Plastic and Reconstructive Surgery and Hand Surgery, 2003, 37, 174-175.	0.6	37
95	Maleimide Is a Potent Inhibitor of Topoisomerase II in Vitro and in Vivo: A New Mode of Catalytic Inhibition. Molecular Pharmacology, 2002, 61, 1235-1243.	2.3	46
96	Dexrazoxane is a potent and specific inhibitor of anthracycline induced subcutaneous lesions in mice. Annals of Oncology, 2001, 12, 405-410.	1.2	52
97	Granisetron compared with prednisolone plus metopimazine as anti-emetic prophylaxis during multiple cycles of moderately emetogenic chemotherapy. British Journal of Cancer, 1999, 80, 412-418.	6.4	25
98	Twenty-five years of chemotherapy in small cell lung cancer sends us back to the laboratory. Cancer Treatment Reviews, 1999, 25, 377-386.	7.7	7
99	Brain relapses in chemotherapy-treated small cell lung cancer: a retrospective review of two time-dose regimens of therapeutic brain irradiation. Lung Cancer, 1996, 15, 171-181.	2.0	11
100	Asbestos-induced lung injury among danish jewelry workers. American Journal of Industrial Medicine, 1994, 26, 755-758.	2.1	5